Building the Future of Enterprise AI
We are a specialized holding company focused exclusively on AI infrastructure for regulated, mission-critical industries where reliability isn't optional—it's foundational.
Our Story
Founded in 2026, Genox Holdings emerged from a simple observation: while AI applications proliferated, enterprise-grade AI infrastructure—especially for regulated industries—remained fragmented and immature.
We don't build AI chatbots or recommendation engines. We build the infrastructure layer that enables hospitals to deploy clinical AI safely, financial institutions to run algorithmic trading systems reliably, and enterprises to orchestrate AI workloads at scale.
Our holding company structure allows us to focus deeply on industry-specific challenges while sharing core infrastructure, compliance frameworks, and operational excellence across platforms.
Founded
Platform Companies
Infrastructure Focus
First Platform Launch
Our Philosophy
Three core beliefs guide everything we build
AI isn't a feature layer—it's foundational infrastructure that requires the same engineering discipline as databases, networks, and operating systems. We build accordingly.
HIPAA, SOC 2, and ISO 27001 aren't constraints—they're design specifications. We architect compliance from the kernel level, not as an afterthought.
Helix Medical Intelligence has different requirements than trading AI. One platform cannot serve all use cases excellently. We specialize deeply rather than generalize poorly.
Leadership Team
Experienced infrastructure engineers and domain experts
Former infrastructure leads from
Large-scale distributed systems, Cloud Infrastructure, ML Platform Engineering
Healthcare, Financial Services, Cybersecurity
Deep regulatory and operational knowledge in target verticals
Current Status
All platforms are currently in pre-production development. We are building towards production-grade systems with proper regulatory certifications, security frameworks, and operational excellence.
Our first platform, Genox AI Medical, is targeting initial release in Q3 2026 with FDA compliance pathways and HIPAA certification.